openPR Logo
Press release

Hyperphosphatemia Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2032

09-21-2024 06:43 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Hyperphosphatemia Market

Hyperphosphatemia Market

The Hyperphosphatemia Market Size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Phosphate Therapeutics, Bayer, Shire, Kyowa Kirin Co Ltd, Shanghai Alebund Pharmaceuticals Limited, Ardelyx, Kissei Pharmaceutical Co. Ltd., Taisho Pharmaceutical Co. Ltd., Sanofi, Chugai Pharmaceutical, Astellas Pharma Inc., Alebund Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, KDL Inc., Denver Nephrologists, CM&D Pharma Limited, Daiichi Sankyo Inc.

[Nevada, United States] - DelveInsight's "Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast 2032." report offers a detailed examination of Hyperphosphatemia, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Hyperphosphatemia Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/hyperphosphatemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Hyperphosphatemia Market Report:
The Hyperphosphatemia market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
In July, 2024: USRC Kidney Research announced a 9-month randomized, double-blind, placebo-controlled study to compare the effect of fixed dose ferric citrate versus placebo in patients with advanced chronic kidney disease (eGFR ≤20 ml/min/1.73m2) on the composite endpoint of time to initiation of maintenance dialysis or all-cause mortality.
In April, 2024: Sinomune Pharmaceutical Co., Ltd announced that a study will take place to evaluate the efficacy and safety of ferric citrate tablets in the control of serum phosphorus levels in patients with chronic kidney disease undergoing hemodialysis.
In March, 2024: Keryx Biopharmaceuticals announced that a study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
According to DelveInsight, in 2023, in the United States, the prevalent cases of End-Stage Renal Disease (ESRD) were found to be ~805,000 cases and patients with ESRD on dialysis accounted for ~572,000 cases.
Moreover, in the total population of CDK stages I-II, 279 patients (1.4%) had hyperphosphatemia while 312 patients (2.3%) of the total population of CDK stages III-V had hyperphosphatemia.
Key Hyperphosphatemia Companies are as follows: Phosphate Therapeutics, Bayer, Shire, Kyowa Kirin Co Ltd, Shanghai Alebund Pharmaceuticals Limited, Ardelyx, Kissei Pharmaceutical Co. Ltd., Taisho Pharmaceutical Co. Ltd., Sanofi, Chugai Pharmaceutical, Astellas Pharma Inc., Alebund Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, KDL Inc., Denver Nephrologists, CM&D Pharma Limited, Daiichi Sankyo Inc.
Key Hyperphosphatemia Therapies are as follow: PT20, KHK7791, VS-505, Sevelamer Carbonate, Tenapanor, Sevelamer Carbonate:, Sevelamer Carbonate (GZ419831), Lanthanum Carbonate (BAY77-1931), Ferric Citrate, TS-172 10mg bid, AP-306
Launching multiple stage Hyperphosphatemia pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Hyperphosphatemia market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Hyperphosphatemia Overview:
Hyperphosphatemia is associated with increased prevalence of cardiovascular diseases and mortality rates. In patients with good renal function, renal phosphate excretion can be increased through extracellular volume expansion by saline infusion and diuretics.

Hyperphosphatemia Epidemiology Segmentation:
The Hyperphosphatemia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Hyperphosphatemia Total Prevalence
Hyperphosphatemia Prevalent Cases by severity
Hyperphosphatemia Gender-specific Prevalence
Hyperphosphatemia Diagnosed Cases of Episodic and Chronic

For more information about Hyperphosphatemia companies working in the treatment market, visit: https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Hyperphosphatemia Treatment Market
Treatment for hyperphosphatemia depends on the underlying condition. For people with kidney disease, a combination of diet and medication is used to keep phosphate levels under control. In patients with good renal function, renal phosphate excretion can be increased through extracellular volume expansion by saline infusion and diuretics. If renal function is impaired, it is an indication for hemodialysis.

Hyperphosphatemia Market Insights
Hyperphosphatemia, characterized by elevated phosphate levels in the blood, is commonly associated with chronic kidney disease (CKD) and other metabolic disorders. As the prevalence of CKD rises globally, the hyperphosphatemia market is experiencing significant growth. This article explores the latest market data, trends, and therapeutic approaches.
Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @
https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Hyperphosphatemia Drugs Uptake
XPHOZAH (tenapanor) discovered and developed by Ardelyx, is a first-inclass, phosphate absorption inhibitor with a differentiated mechanism of action that acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3).
RENVELA (sevelamer carbonate) is used to control phosphorus levels in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis
FOSRENOL (lanthanum carbonate) is a phosphate binder. It is a large pill that requires thorough chewing to avoid choking and other gastrointestinal adverse effects.

Hyperphosphatemia Therapies and Companies:
PT20: Phosphate Therapeutics
KHK7791: Kyowa Kirin Co., Ltd.
VS-505, Sevelamer Carbonate: Shanghai Alebund Pharmaceuticals Limited
Tenapanor, Sevelamer Carbonate: Ardelyx
Sevelamer Carbonate (GZ419831): Sanofi
Lanthanum Carbonate (BAY77-1931): Bayer
Ferric Citrate: Kaiser Permanente
TS-172 10mg bid: Taisho Pharmaceutical Co., Ltd.
AP-306: Alebund Pharmaceuticals

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Hyperphosphatemia Market Drivers:
Increasing Prevalence of Chronic Kidney Disease
Growing Awareness and Early Diagnosis
Expanding Geriatric Population
Increased Focus on Research & Development

Hyperphosphatemia Market Barriers:
Side Effects of Existing Therapies
Low Awareness in Developing Regions
Limited Availability of Treatment Options

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Hyperphosphatemia Market Report:
Study Period: 2019-2032
Coverage: 7MM (The United States, EU5, and Japan)
Key Hyperphosphatemia Companies: Phosphate Therapeutics, Bayer, Shire, Kyowa Kirin Co Ltd, Shanghai Alebund Pharmaceuticals Limited, Ardelyx, Kissei Pharmaceutical Co. Ltd., Taisho Pharmaceutical Co. Ltd., Sanofi, Chugai Pharmaceutical, Astellas Pharma Inc., Alebund Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, KDL Inc., Denver Nephrologists, CM&D Pharma Limited, Daiichi Sankyo Inc.
Key Hyperphosphatemia Therapies: PT20, KHK7791, VS-505, Sevelamer Carbonate, Tenapanor, Sevelamer Carbonate:, Sevelamer Carbonate (GZ419831), Lanthanum Carbonate (BAY77-1931), Ferric Citrate, TS-172 10mg bid, AP-306
Hyperphosphatemia Therapeutic Assessment: Current marketed and emerging therapies
Hyperphosphatemia Market Dynamics: Hyperphosphatemia Market drivers and Hyperphosphatemia barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Hyperphosphatemia Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Hyperphosphatemia market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Hyperphosphatemia Executive Summary
3. Competitive Intelligence Analysis for Hyperphosphatemia
4. Hyperphosphatemia Market Overview at a Glance
5. Hyperphosphatemia Market Disease Background and Overview
6. Hyperphosphatemia Patient Journey
7. Hyperphosphatemia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Hyperphosphatemia Unmet Needs
10. Key Endpoints of Hyperphosphatemia Treatment
11. Hyperphosphatemia Marketed Products
12. Hyperphosphatemia Emerging Therapies
13. Hyperphosphatemia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Hyperphosphatemia Market Outlook
16. Hyperphosphatemia Market Access and Reimbursement Overview
17. Hyperphosphatemia KOL Views
18. Hyperphosphatemia Market Drivers
19. Hyperphosphatemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2024

Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hyperphosphatemia Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2032 here

News-ID: 3663297 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Hyperphosphatemia

Sustainable Growth Of Hyperphosphatemia Treatment Market Amid Rising Chronic Dis …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations. What Will the Hyperphosphatemia Treatment Industry Market Size Be by 2025? The market for hyperphosphatemia treatment has expanded quickly in recent years. Its size is set to increase from $4.56 billion in 2024 to $5.13 billion in 2025, with a compound annual growth rate (CAGR) of 12.4%. The extension during the historical period is
Key Influencer in the Hyperphosphatemia Treatment Market 2025: Sustainable Growt …
What industry-specific factors are fueling the growth of the hyperphosphatemia treatment market? The rise in chronic illnesses among patients is boosting the hyperphosphatemia treatment market. Conditions like cardiovascular and kidney diseases, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer all fall under the category of chronic diseases, which are non-communicable and demand long-term management. For instance, the World Health Organization reported in September 2023 that 74% of the 41 million global deaths
Hyperphosphatemia Pipeline Insight Report 2024
(Albany, United States) As per DelveInsight's assessment, globally, the Hyperphosphatemia Pipeline constitutes 15+ key companies continuously working towards developing 15+ Hyperphosphatemia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight. In the Hyperphosphatemia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Hyperphosphatemia NDA approvals (if any), and product development activities comprising
Hyperphosphatemia Drugs Market to Witness Robust Expansion by 2029
The Hyperphosphatemia Drugs Market size is expected to grow at an annual average of CAGR 2% during the forecast period (2023-2029). Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic uncontrolled diabetes, and low
Hyperphosphatemia- Market Insight, Epidemiology and Market Forecast -2030
Hyperphosphatemia Market research report is the new statistical data source added by Infinity Business Insights. Hyperphosphatemia is a condition in which your blood contains a lot of phosphate (or phosphorus). Phosphate is an electrolyte, a chemically charged compound containing the mineral phosphorus. Phosphate is required by your body to strengthen your bones and teeth, create energy, and construct cell membranes. Phosphate, on the other hand, in excess can cause bone
Hyperphosphatemia Drugs Market Opportunity Analysis, 2018 - 2026
Hyperphosphatemia is a condition caused due to high level of phosphate or phosphorous in the blood. Phosphate is a chemical found in body and contain mineral called phosphorous. Phosphorus mineral is very important for the development of teeth and bones and also convert food into energy for body. Phosphate is mainly found in the teeth, bones, inside the cells, and in very smaller amounts in the blood. Kidney functions for